Greylin Investment Management’s Meridian Bioscience Inc VIVO Stock Holding History

Greylin Investment Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-47,585	Closed	-$709K	–	87
2018 Q3	$709K	Sell	47,585 -40,050	-46%	-$621K	0.15%	47
2018 Q2	$1.39M	Sell	87,635 -1,525	-2%	-$22.7K	0.3%	40
2018 Q1	$1.27M	Buy	89,160 +5,550	+7%	+$82.1K	0.27%	38
2017 Q4	$1.17M	Buy	83,610 +11,275	+16%	+$165K	0.25%	43
2017 Q3	$1.03M	Buy	72,335 +11,150	+18%	+$159K	0.24%	43
2017 Q2	$964K	Buy	61,185 +10,050	+20%	+$145K	0.22%	43
2017 Q1	$706K	Sell	51,135 -500	-1%	-$6.99K	0.16%	48
2016 Q4	$914K	Buy	51,635 +19,825	+62%	+$348K	0.22%	41
2016 Q3	$614K	Buy	31,810 +10,475	+49%	+$205K	0.15%	51
2016 Q2	$416K	Buy	+21,335	New	+$418K	0.1%	54
2016 Q1	–	Sell	-9,835	Closed	-$202K	–	78
2015 Q4	$202K	Buy	+9,835	New	+$189K	0.05%	71

Other funds holding VIVO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SFM

Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

Greylin Investment Management's VIVO Position: Q4 2018 in Review

Greylin Investment Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2018, closing a stake of 47,585 shares — an estimated $709K sold.

Greylin Investment Management first reported a position in VIVO in Q4 2015 and held it in 11 quarters. The position peaked at $1.39M in Q2 2018. 191 funds tracked by Wall St. Rank hold VIVO as of Q4 2018.

Greylin Investment Management reported no remaining Meridian Bioscience Inc position as of Q4 2018 after selling out during the quarter.
Greylin Investment Management sold 47,585 Meridian Bioscience Inc shares in Q4 2018, an estimated $709K.
Greylin Investment Management first reported a position in Meridian Bioscience Inc in Q4 2015 and held it in 11 quarters.
Greylin Investment Management's Meridian Bioscience Inc position peaked at $1.39M in Q2 2018.
191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2018.

Based on Greylin Investment Management's 13F filing for Q4 2018, filed 14 Jan 2019.